Objectives: To compare the characteristics and hospital outcomes of patients with an acute exacerbation of chronic obstructive pulmonary disease treated in the ICU with initial noninvasive ventilation or invasive mechanical ventilation. Design: Retrospective, multicenter cohort study of prospectively collected data. We used propensity matching to compare the outcomes of patients treated with noninvasive ventilation to those treated with invasive mechanical ventilation. We also assessed predictors for noninvasive ventilation failure. Setting: Thirty-eight hospitals participating in the Acute Physiology and Chronic Health Evaluation database from 2008 through 2012. Subjects: A total of 3,520 patients with a diagnosis of chronic obstructive pulmonary disease exacerbation including 27.7% who received noninvasive ventilation and 45.5% who received invasive mechanical ventilation. Interventions: None. Measurements and Main Results: Noninvasive ventilation failure was recorded in 13.7% from patients ventilated noninvasively. Hospital mortality was 7.4% for patients treated with noninvasive ventilation; 16.1% for those treated with invasive mechanical ventilation; and 22.5% for those who failed noninvasive ventilation. In the propensity-matched analysis, patients initially treated with noninvasive ventilation had a 41% lower risk of death compared with those treated with invasive mechanical ventilation (relative risk, 0.59; 95% CI, 0.36-0.97). Factors that were independently associated with noninvasive ventilation failure were Simplified Acute Physiology Score II (relative risk = 1.04 per point increase; 95% CI, 1.03-1.04) and the presence of cancer (2.29; 95% CI, 0.96-5.45). Conclusions: Among critically ill adults with chronic obstructive pulmonary disease exacerbation, the receipt of noninvasive ventilation was associated with a lower risk of in-hospital mortality compared with that of invasive mechanical ventilation; noninvasive ventilation failure was associated with the worst outcomes.
These results support the use of noninvasive ventilation as a first-line therapy in appropriately selected critically ill patients with chronic obstructive pulmonary disease while also highlighting the risks associated with noninvasive ventilation failure and the need to be cautious in the face of severe disease. (Crit Care Med 2015; 43:1386-1394) Key Words: acute respiratory failure; chronic obstructive pulmonary disease; intensive care unit; invasive mechanical ventilation; noninvasive ventilation; Simplified Acute Physiology Score II C hronic obstructive pulmonary disease (COPD) is a highly prevalent condition that is responsible for approximately 1 million hospitalizations each year, and it is the third leading cause of death in the United States (1) (2) (3) . There is a wide range of disease severity among hospitalized patients with an acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), ranging from brief hospital admission to prolonged hospitalization and death (4, 5) . Approximately 12-18% of patients hospitalized with an AE-COPD are treated in the ICU (6) and mortality in this population approaches 15% (5) .
The efficacy of noninvasive ventilation (NIV) in patients with AE-COPD has been extensively studied. Several randomized controlled trials (RCTs) (7-9) and meta-analyses (10, 11) found a reduction in intubation rate, hospitalacquired pneumonia, and mortality when NIV was added to supportive care. A number of guidelines strongly recommend NIV versus standard care alone in moderate to severe COPD exacerbation. However, only two small RCTs directly compared the efficacy of NIV and invasive mechanical ventilation (IMV) and found that NIV use resulted in fewer complications and lower readmission rate without changes in mortality (12, 13) . One survey study of 99 patients with AE-COPD admitted to 42 French ICUs (14) and one recent large U.S. study using an administrative dataset (15) showed that NIV use was associated with significant reduction in mortality compared with IMV. Because of insufficient evidence, the Canadian Practice Guidelines and the U.S. Agency for Healthcare Research and Quality comparative effectiveness review make no recommendations about the use of NIV versus IMV in patients with severe acute respiratory failure (ARF) secondary to COPD (16, 17) .
There are limited recent data about the use of NIV and its associated outcomes in patients with severe AE-COPD admitted to ICU, and what has been learned recently about the comparative effectiveness of NIV to IMV comes mainly from studies based only on claims data.
We sought to take advantage of a large, multicenter ICU database that contains physiological data to compare the characteristics and short-term outcomes of patients hospitalized with severe COPD exacerbation and treated with NIV and IMV. We hypothesized that after adjusting for severity of illness and other patient and hospital characteristics, patients treated with NIV would have better outcomes than patients treated with IMV.
METHODS

Design, Setting, and Subjects
We conducted a cohort study of patients hospitalized from January 2008 to December 2012 at 38 structurally diverse U.S. hospitals that participate in the Acute Physiology and Chronic Health Evaluation (APACHE) outcomes database. The APACHE project is a U.S. prospective, multicenter, clinical registry that was created to provide feedback to hospital ICUs on risk-adjusted outcomes for quality improvement purposes. All patient data are entered on-site by trained data collectors using specific software and standardized definitions. The database has been used extensively for research (18, 19) .
We included patients 40 years old or older with a primary diagnosis of bronchitis/emphysema or respiratory arrest paired with a secondary diagnosis of COPD. In the APACHE database, the admission diagnosis reflects the primary reason for ICU admission and is selected by a physician within the first 24 hours. We did not include patients with any other primary diagnosis (e.g., pneumonia or sepsis with a secondary diagnosis of COPD) because our primary goal was to analyze patients with ARF secondary to COPD and not patients with comorbid COPD.
Patient and Hospital Information
Patient demographics, location prior to ICU admission, detailed clinical and physiological variables, duration and type of ventilator therapy, advance care directives, readmission to ICU, discharge status, and hospital characteristics were collected. The severity of illness was assessed using the Simplified Acute Physiology Score (SAPS) II (20) . Only comorbidities known to impact ICU mortality are collected in the APACHE dataset, including immunosuppression, cancer, cirrhosis, COPD, diabetes, and renal disease requiring renal replacement therapy. Severity of COPD is assessed based on the functional limitation caused by the chronic pulmonary disease and is classified as: "severe," "moderate," or "no limitation with activities of daily living." Time to discharge from the ICU and from the hospital and to death was recorded for all patients. The majority of the variables were complete, and only a few variables were not recorded in all patients (e.g., advance directives, albumin, and Pao 2 ).
Receipt of Mechanical Ventilation
The mode of initial mechanical ventilation at admission to ICU was the primary exposure variable. For the purpose of this study, we classified patients according to ventilatory strategy into two groups: "NIV Initial" (patients started on NIV) and "IMV Initial" (patients who were initially intubated). We noted any changes in the type of mechanical ventilation during the hospitalization to ICU. Patients were considered to have failed NIV if they were intubated after an NIV trial. We excluded from the NIV or IMV groups but not from the study in general, a small number of cases in which we were unable to determine the order of ventilation. For the comparison of the outcomes of NIV to IMV, we restricted analysis to patients admitted to ICU from the emergency department (ED); we excluded patients transferred from the hospital ward because their outcomes were more likely to be influenced by management prior to ICU admission. In a sensitivity analysis, we included all patients admitted to the ICU irrespective of the source of admission.
Outcomes
The primary outcomes were ICU and in-hospital mortality. Secondary outcomes were ICU and hospital length of stay (LOS).
analysis
We calculated descriptive statistics including counts and percentages for categorical factors and means, sds, and percentiles for continuous factors to characterize the study population. Chi-square inference tests, t tests, and nonparametric analogs were used to compare patients and hospital characteristics, including demographics, physiological data, and outcomes for patients who received NIV or IMV as initial ventilation strategies.
To adjust for confounding when comparing outcomes by initial ventilation strategy, we first created a multilevel mixed-effects (hierarchical) logistic regression model with hospitals as a random effect to estimate the propensity of initial NIV treatment as the outcome. In the propensity score model, the predictors were age, patient demographics, comorbidities, and SAPS II as shown in Table 1 . We then matched patients who received NIV initial to patients with similar propensity who received IMV to compare mortality using a 5:1 Greedy matching algorithm.
We performed a multivariable logistic regression analysis to identify factors associated with NIV failure also adjusting for age, patient demographics, comorbidities, location prior to admission to the ICU, and SAPS II. For this analysis, we included patients without any advanced directive restriction and all patients with NIV failure (although for a small number of patients the code status was not specified). In a sensitivity analysis, we restricted the cohort to only patients with a known code status.
Stata/MP 13.1 for Windows (StataCorp, College Station, TX) was used for statistical analyses.
This project was approved by the Baystate Medical Center Institutional Review Board for the Protection of Human Subjects.
RESUlTS
Study Population Characteristics
A total of 3,520 patients from 38 hospitals were included in this analysis (Fig. 1) were women, 84.0% were white, and the median SAPS II was 37. The majority of admissions were from the ED. Sixty-two percent of patients were admitted to hospitals with more than 400 beds, and 23% were admitted to nonteaching hospitals (Table 1) . At the time of ICU admission, 918 patients (26.1%) were not ventilated, 974 (27.7%) were treated with NIV, and 1,603 (45.5%) were treated with IMV. Twenty-five patients (0.7%) received both NIV and IMV on the same first day and so were indeterminate as to what treatment was first started. NIV failure was recorded in 13.7% from patients ventilated noninvasively.
The median ICU and hospital lengths of stay were 2.7 days (interquartile range [IQR], 1.5, 5.1 d) and 7.3 days (IQR, 4.6, 15.9 d), respectively, and 6.5% of patients were readmitted to the ICU during their same hospitalization. Patients spent a median of 2.2 days on IMV, and 15% of patients were on IMV for more than 7 days. Overall ICU and hospital mortality rates were 6.5% and 11.1%, respectively.
Comparison of NIV and IMV Therapy
Main demographic and physiological characteristics of all patients admitted to an ICU meeting the inclusion criteria for COPD treated either with NIV or IMV at admission to the ICU are presented in Table 1 . Compared with patients initially treated with IMV, patients treated with NIV had lower SAPS II, were more likely to be admitted from the ED, and have a donot-resuscitate order.
The receipt of NIV was associated with lower ICU and hospital mortality compared with the receipt of IMV (3.1% vs 10.5% and 7.4% vs 16.1%, respectively); patients treated with NIV had shorter ICU and hospital LOS and were less likely to be discharged to nursing home. When we analyzed LOS for survivors by age, we found that patients who received NIV had a shorter LOS than those receiving IMV across all ages. Among NIV patients, LOS tended to be longer at both extremes of age (Fig. 2) .
In the propensity-matched analysis, which included patients admitted directly from the ED, we found that those treated with NIV had a 61% lower risk of dying in the ICU (relative risk [RR], 0.39; 95% CI, 0.18-0.85) and 41% lower risk of dying in the hospital (RR, 0.59; 95% CI, 0.36-0.97) compared with patients treated with IMV. The propensity analysis was based on 389 matched pairs, which means that 71.1% of the eligible NIV patients were successfully matched to an IMV patient within a propensity difference no larger than 0.1. All predictors in the model were statistically nonsignificant between IMV and NIV after matching. As a sensitivity analysis, we recalculated the propensity score analysis using the same predictors on all patients and not just those from the ED. NIV patients had a statistically similar survival benefit (RR = 0.63; 95% CI, 0.46, 0.86; p = 0.004) when compared to the subset directly admitted from the ED. This result is based on 679 matched pairs or 69.7% of the eligible NIV patients.
Patients who were transitioned from NIV to IMV had the highest mortality (13.5% in ICU and 22.5% in the hospital) and the longest hospital stay ( Table 2) . Compared with patients who avoided intubation, those who failed NIV had higher respiratory rate, higher SAPS II, and were more likely to have a Glasgow coma score less than 15. Table 3 presents these unadjusted results. Factors that were independently associated with NIV failure were SAPS II (RR = 1.04; per point 95% CI, 1.03-1.04) and the presence of cancer (2.29; 95% CI, 0.96-2.44) ( Table 4) . Age was not significantly associated with NIV failure. These results were similar in a sensitivity analysis that was restricted to patients with known advanced directives (Table 4 ). When we grouped SAPS II by quintiles, we observed that the rate of NIV failure increased as the SAPS II increased (Fig. 3) .
DISCUSSION
In this contemporary observational study of more than 3,000 patients admitted with an AE-COPD to 38 ICUs in the United States, we found that after adjusting for severity of illness using propensity score matching, receipt of NIV was associated with lower ICU and in-hospital mortality and shorter LOS compared with IMV. Patients who failed NIV had the worst outcomes, and SAPS II was independently associated with the need for intubation.
Several current guidelines recommend early use of NIV in patients hospitalized with moderate to severe AE-COPD based on the results of RCTs which found that NIV improves outcomes compared with supportive care alone (16, (21) (22) (23) . For example, the Canadian Practice guidelines published in 2011 give a level 1A recommendation for NIV use in severe exacerbation of COPD versus standard therapy (no ventilation) (17) . However, the guidelines state: "we make no recommendation about the use of NIV versus conventional mechanical ventilation in patients who have a severe COPD exacerbation that requires ventilator support, because of insufficient evidence." There are only two RCTs which compared NIV with IMV; the small number of studies may reflect the general current belief that avoiding invasive ventilation is strongly desired. These trials, which included patients with severe ARF who failed standard treatment, found that NIV lowered hospital-acquired pneumonia but did not reduce mortality or LOS and had a high rate of NIV failure (12, 24) .
Our results are consistent with those from a survey study in 42 ICUs in France in 1997 which found that NIV use was associated with lower risk of death than IMV (10% vs 28%). In our study in the propensity-matched analysis, NIV therapy was associated with a 41% lower risk of death than IMV. Our results are also similar with the findings from the study by Tsai et al (15), a recent retrospective study of 67,000 ED visits for AE-COPD with ARF in United States; in this study, patients treated with NIV alone had a mortality rate of 8% compared with 16% in patients treated with IMV alone. Although we did reach some of the same conclusions as this study, our target population was different, and our methodology was much stronger and overcomes a number of the biases in the Nationwide Inpatient Sample, on which the work by Tsai et al (15) was based. In our study, the percentage of patients treated with NIV who avoided endotracheal intubation was 86%, and the SAPS II was predictive of NIV failure, which concurs with prior research (25) . In a prospective randomized study, Antonelli et al (26) reported that a SAPS II greater than 34 was independently associated with the need for endotracheal intubation. Consistent with the findings of Antonelli et al (26) , we also found that the likelihood of NIV failure rose sharply at higher SAPS II. Patients who transition from NIV to IMV had a high ICU and hospital mortality in keeping with the results from other studies (15, 27) .
Study Strengths and limitations
This study has several strengths. To the best of our knowledge, this is the largest contemporary U.S. multicenter study of patients admitted to intensive care with respiratory failure secondary to an acute COPD exacerbation and provides an estimate of the ventilation practices and outcomes in the ICU for these patients. All the data were collected prospectively by trained, on-site investigators, the advance directive status was known, and the primary diagnosis was assigned at the time of admission, not retrospectively by coders. The dataset comprises clinical and laboratory data, and the SAPS II is calculated allowing better adjustment for the severity of illness than other observational studies with administrative datasets. This study has also several limitations. First, although a mixture of teaching and nonteaching and small and large hospitals were included in this database, hospitals participating in the APACHE project may not be representative of all hospitals in the United States. Second, we did not have spirometric data. However, all diagnoses of COPD were assigned by an intensivist, and our comparative analysis included only ventilated patients with a diagnosis of COPD and so their COPD was most likely severe. Third, although we adjusted for the SAPS II and other patient characteristics using propensity score matching, the survival benefit we observed with NIV use assumes that all patients treated with NIV or IMV had similar degrees of severity of respiratory failure and this may not have been true. This was an observational study, and although we adjusted for severity via SAPS II and other physiological variables, we cannot exclude that unmeasured confounders at the patient and hospital level distorted our findings. In addition, the initial decision for NIV or IMV was based on physician judgment rather than on unified criteria. Fourth, unlike most randomized studies in this area, the population included in this study is of patients receiving ventilatory support for an exacerbation of COPD and not necessarily with hypercapnic acidotic exacerbation. Lastly, we examined in-hospital mortality because we did not have any information regarding the survival of patients with COPD after discharge though we note that 90-day mortality has been reported to be high.
CONClUSIONS
Our observational study suggested that NIV use is associated with lower mortality than IMV use in patients with severe ARF secondary to an exacerbation of COPD and that NIV failure is associated with the worst outcomes. These results support the use of NIV as a first-line therapy in appropriately selected critically ill patients with COPD while also highlighting the risks associated with NIV failure and the need to be cautious in the face of severe disease.
aCKNOWlEDGMENTS
We thank Andrew A. Kramer, PhD, from Cerner Corporation for providing the data for the study. Although Cerner Corporation administers the data, the authors are exclusively responsible for the analysis and conclusion of the study. In the primary analysis, we assume that all patients with invasive mechanical ventilation after NIV are failures, even if their do-not-resuscitate code status is unknown. In the sensitivity analysis, we only look at patients with known "full code" (no code restriction) status. 
